Unsaturated glycoceramides as molecular carriers for mucosal drug delivery of GLP-1
Graphical abstract
Introduction
One of the major difficulties in effectively treating Type II diabetes and other chronic diseases involves patient compliance for lifelong management by frequent injections of therapeutic peptides or proteins. Two of the most potent therapeutic peptides used to control blood glucose in Type II diabetes, insulin and analogs of the incretin hormone GLP-1, are impermeant to epithelial barriers at mucosal surfaces and require delivery by subcutaneous (SC) injection. Optimal control of blood sugar levels by these agents entails frequent daily injections, which can be sometimes missed by patients due to lifestyle and the social stigma of self-injection in public. Thus, much effort has gone into the development of technologies to render these therapeutic peptides absorbable across mucosal surfaces for efficient delivery without self-injection and with improved patient compliance. Here, we test if our recent discoveries on glycosphingolipid trafficking in polarized epithelial cells [1], [2] can be applied to convert GLP-1 into a molecule suitable for mucosal absorption.
The gastrointestinal, respiratory, and genitourinary tracts represent vast mucosal surfaces where host tissues are separated from the environment only by a delicate but highly effective single layer of columnar epithelial cells, joined by tight junctions that are impermeable to proteins and even small peptides. Proteins non-specifically taken up into the epithelial cell by endocytosis are generally transported to lysosomes for degradation, establishing an effective barrier to uncontrolled entry of these materials into the body and the maintenance of systemic homeostasis. So far, the lack of rational and efficient methods to circumvent this barrier has prevented the application of most therapeutic proteins for efficient mucosal drug delivery.
Glucagon-like peptide-1 (GLP-1) is an incretin hormone derived from the transcription product of the pro-glucagon gene and is primarily released from L-cells of the intestinal mucosa [3]. This hormone has lasting and potent antihyperglycemic actions by inducing glucose-dependent stimulation of insulin secretion while suppressing glucagon secretion, as well as restoring glucose sensitivity of pancreatic β-cells while it inhibits gastric secretion and motility to protract carbohydrate absorption and contribute to satiety [4]. Once in the circulation, GLP-1 is rapidly degraded (with a half-life of less than 2 min). Thus, the majority of pharmaceutical approaches have been focused on developing longer-acting analogs of GLP-1 [5]. Exenatide, a synthetic form of the peptide exendin-4 from lizard saliva, is a potent GLP-1 receptor (GLP-1R) agonist on the market for Type 2 diabetes [6] and even has been developed into a once-weekly formulation by encapsulation in Poly-(d,l-Lactide-Co-Glycolide) Microspheres [7], [8]. Another marketed example is liraglutide, an acylated human GLP-1 analog [9]. Although these degradation-resistant GLP-1R agonists are excellent agents for the treatment of diabetes, they still require daily to weekly delivery by injection. Developing an oral long-acting GLP-1 formulation would allow patients to manage their blood glucose levels by a non-parenteral form of administration.
We recently discovered that the structure of the ceramide domain of the glycosphingolipid GM1, the receptor for cholera toxin that mediates cell entry, dictates intracellular trafficking and the subcellular localization of this lipid in mammalian cells [1], [2]. GM1 is comprised of two major domains: the hydrophilic oligosaccharide head group that protrudes from the cell membrane into the extra-cellular space; and the hydrophobic ceramide lipid tail that anchors the molecule within the membrane bilayer. Native GM1 ceramides in human cells show heterogeneity in structure, most typically in length of the fatty acid carbon chain and degree of saturation [10].
When exogenously applied to epithelial cells, the GM1-ceramide species that contain a short chain C12:0 or an unsaturated C16:1 fatty acid in the ceramide domain enter the early sorting/recycling endosome from where they are sorted to other destinations [1]. The GM1-ceramide species with long, saturated C18:0 fatty acyl chains are transported instead to the lysosome, presumably for degradation. In simple polarized epithelial cells that form the single-cell thick monolayer lining mucosal surfaces, exogenously added GM1 species with short or unsaturated ceramide domains are transported from the apical (luminal) membrane across the cell to the basolateral (serosal) membrane by transcytosis, following a transcellular pathway leading to absorption [2].
Here, we test if GM1 can be used as a molecular carrier to deliver analogs of GLP-1 across epithelial barriers by harnessing these properties of endogenous sphingolipid trafficking. We linked the GLP-1 peptide to the extracellular domain of different GM1 species with ceramide domains of known structure, synthesized as described before [1]. We found that ceramide-directed trafficking remained intact after GM1 attachment to a therapeutic analog of GLP-1. Fusion molecules with short- or cis-unsaturated ceramide domains entered epithelial cells by endocytosis, trafficked to the recycling endosome, and reached the basolateral membrane of polarized cells by transcytosis; suggesting that specific glycosphingolipids may, indeed, be harnessed as molecular vehicles for mucosal delivery of therapeutic peptides.
Section snippets
Materials and reagents
Defatted bovine serum albumin (df-BSA), fetal bovine serum (FBS), Hank's balanced salts solution (HBSS) and 2-nitrophenyl β-d-galactopyranoside were from Sigma-Aldrich (St. Louis, MO). Steadylite reagent was from PerkinElmer (Boston, MA), the Cytotox ONE™ kit from Promega (Madison, WI). 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was obtained from Invitrogen (Eugene, OR) and wheat germ agglutinin labeled Alexa594 (WGA-Alexa594) from Molecular Probes (Eugene, OR). The
Synthesis and characterization of GLP-1 analogs and GLP-1-GM1 fusion variants
We synthesized a stable GLP-1 analog containing α-amino-isobutyric acids (Aib) at residues 8 and 33 to allow for increased half-life [17] (Fig. 1A). The peptide was extended at the C-terminus to incorporate a short linker sequence followed by two modified lysine residues. The penultimate amino acid contained a biotin molecule linked via a 0.5 kDa PEG spacer, allowing us to track the molecule biochemically and by microscopy. The terminal amino acid contained the same PEG spacer ending with an
Acknowledgments
We thank J.P. Fortin, A.S. Kopin and M. Beinborn for the plasmids required for the hGLP-1 bioactivity assay and their aid in setting up this assay; New England Peptide NEP for peptide bioconjugation to GM1; the entire Lencer lab group for helpful discussions; R. Massol for help with confocal microscopy; and M.A. Wurbel for help with flow cytometry. This study was funded by NIH grants R21 DK090603 and RO1 DK48106, a Technology Innovation and Development grant and a Translational Research grant
References (41)
- et al.
Lipid sorting by ceramide structure from plasma membrane to ER for the cholera toxin receptor ganglioside GM1
Dev. Cell
(2012) - et al.
Ganglioside GM1-mediated transcytosis of cholera toxin bypasses the retrograde pathway and depends on the structure of the ceramide domain
J. Biol. Chem.
(2013) - et al.
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
Lancet
(2006) - et al.
Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study
Lancet
(2013) - et al.
A simple method for the isolation and purification of total lipides from animal tissues
J. Biol. Chem.
(1957) - et al.
A human glucagon-like peptide-1 receptor polymorphism results in reduced agonist responsiveness
Regul. Pept.
(2005) - et al.
Processing of human intestinal prolactase to an intermediate form by furin or by a furin-like proprotein convertase
J. Biol. Chem.
(1998) - et al.
Characterization and quantitative determination of gangliosides and neutral glycosphingolipids in human liver
J. Lipid Res.
(1982) Uptake and metabolism of exogenous glycosphingolipids by cultured cells
Semin. Cell Dev. Biol.
(2001)- et al.
Pharmacokinetics and pharmacodynamics of exenatide following alternate routes of administration
Int. J. Pharm.
(2008)